- Semax is a synthetic ACTH(4-10) analogue studied in preclinical models for its relationship to brain-derived neurotrophic factor signaling, not a compound with established human cognitive outcomes.
- In the indexed Semax literature many studies included female subjects, yet none reported outcomes stratified by sex, so no measured female-specific finding exists.
- No menstrual cycle, hormonal interaction, perimenopause, or pregnancy and lactation safety data for Semax has been indexed, which makes each of those a genuine unknown rather than a reassurance.
Read enough neuropeptide research and a recurring problem surfaces: a compound can accumulate decades of laboratory work and still tell you almost nothing about how it behaves in a woman's body. Semax is a clean example. It is a synthetic analogue of the adrenocorticotropic hormone fragment 4-10, first developed in Russia in the 1980s for neurological and cognitive research, and its short, stabilized structure has made it a durable tool compound. What it does not have is a body of evidence that reports its effects by sex.
The studied mechanism
In preclinical models, Semax has been studied for its relationship to brain-derived neurotrophic factor (BDNF) signaling, the pathway associated with neuronal growth, differentiation, and synaptic plasticity. It has also appeared in work on nerve-growth-factor expression and on dopaminergic and serotonergic signaling, and in models touching cerebral blood flow and neuroinflammation. That places it across several research categories at once while keeping its studied activity relatively defined.
The useful feature for a cognitive catalog is specificity. Rather than acting broadly across many receptor classes, Semax has been characterized against defined pathways, which makes it easier to study in isolation or inside a structured multi-material protocol. None of that, on its own, is a human outcome; it is a description of what investigators have probed.
What the human record actually covers
Human data on Semax is limited, and its research status is best described as early. There is no established therapeutic dose in most jurisdictions, and early-study figures are not a protocol. The compound is supplied and discussed as a research material, not a treatment.
Any dose figures that appear in the Semax literature reflect early studies reported for reference only. This site does not publish personal dosing, titration schedules, or protocols, and nothing here is medical advice.
The female-evidence question
This is where honesty matters most. Across the categories a woman would reasonably ask about, the Semax record is empty rather than reassuring.
- Menstrual cycle: no cycle-interaction data has been indexed.
- Hormonal interactions: no data on estrogen, thyroid, or contraceptive interactions.
- Perimenopause and menopause: no data in perimenopausal or menopausal populations.
- Pregnancy and lactation: no safety data exists, and absence of harm data is not evidence of safety.
- Sex differences: in the indexed literature, many studies included female subjects and none reported sex-stratified outcomes.
The last point is the subtle one. Female subjects were present in the underlying work, but their results were folded into pooled outcomes, so there is nothing to extract. That is a different situation from a compound never tested in females, and it is worth naming precisely: the data was collected, then not reported in a way that answers the question.
For the full derivation of how this compound is graded, and the standalone female-evidence fields as they stand today, see the Semax compound profile. The mechanism is interesting; the sex-stratified evidence is, for now, unwritten, and we would rather show you that blank than fill it.